Figure 3
Expression of CD134 on human NK cells is dependent on interaction with T cells and/or monocytes. (A) PBMCs or purified NK cells were co-cultured with Ramos cells and not treated or treated with rituximab (5 μg/mL) for 24 hours. CD134, CD137 and CD69 expression on NK cells were then examined by flow cytometry. Representative plots shown from triplicate experiments. (B) Increase of %CD134 expression on NK cells within PBMC, and purified NK co-cultures, treated as in (A). The baseline %CD134 expression has been deducted. Each dot represents a different donor, ****P < 0.0001, paired t test. (C) PBMCs or purified NK cells treated with SEB and autologous purified T cells and/or purified monocytes added back. After 24 hours, co-cultures were examined by flow cytometry for CD134 expression on NK cells. n = 3 independent experiments, paired t test, *P < 0.05 (D) PBMCs or purified NK cells were co-cultured with autologous purified B-cells and not treated or treated with rituximab (5 μg/mL) for 24 hours. Co-cultures were then harvested and analysed by flow cytometry for CD134 and CD137 expression.
